CSL - Interest Expense On Debt


CSL reported $215M in Interest Expense on Debt for its fiscal semester ending in December of 2025.





Interest Expense On Debt Change Date
Arca Biopharma USD 504K 246K Sep/2024
Bio Path 130K 95K Sep/2025
Cara Therapeutics 39.02M 4.73M Sep/2025
CSL USD 215M 111M Dec/2025
Curis USD 178K 441K Dec/2023
Esperion Therapeutics USD 22.64M 585K Dec/2025
Immunic 400K 400K Dec/2024
Infinity Pharmaceuticals USD 45K 0 Jun/2023
Minerva Neurosciences USD 2.31M 60K Jun/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
TherapeuticsMD USD 20K 25K Sep/2023